drugset / Trial / NCT04583280

A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV)

NCT04583280

Phase 3 Terminated 28 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to evaluate the efficacy of rilematovir compared to placebo treatment with respect to the clinical outcome on the RSV Recovery Scale (RRS).

Timeline

Start
2021-09-06
Primary completion
2022-03-18
Completion
2022-03-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Rilematovir Other / unclassified Oral